Utama › Kanser Pankreas › Utah › Salt Lake City
Kajian klinikal Kanser Pankreas di Salt Lake City, UT
15 kajian untuk Kanser Pankreas sedang mencari peserta di lokasi dalam dan sekitar Salt Lake City (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Mengambil pesertaFasa 1
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Mengambil pesertaFasa 3
- University of Utah, Huntsman Cancer Institute, Salt Lake City
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Mengambil pesertaFasa 3
- Investigative Site US053, Salt Lake City
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Mengambil pesertaFasa 3
- Utah Cancer Specialists, Salt Lake City
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Mengambil pesertaFasa 1/2
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Mengambil pesertaKajian pemerhatian
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Pancreatic Cancer Early Detection Consortium
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Huntsman Cancer Institute, Salt Lake City
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Mengambil pesertaFasa 1
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Mengambil pesertaFasa 1/2
- Huntsman Cancer Institute, Salt Lake City
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Mengambil peserta
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Mengambil pesertaFasa 1/2
- Huntsman Cancer Institute, Salt Lake City
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Mengambil pesertaFasa 2
- Ohio State University-Telemedicine, Salt Lake City
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Mengambil pesertaFasa 1/2
- Huntsman Cancer Institute, Salt Lake City
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Mengambil pesertaFasa 1/2
- Utah Cancer Specialists (site 203), Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Salt Lake City
Kajian Kanser Pankreas di bandar lain
- Houston, TX61 kajian
- New York City, NY60 kajian
- Boston, MA43 kajian
- Nashville, TN39 kajian
- Los Angeles, CA35 kajian
- St. Louis, MO33 kajian
- Arlington, VA33 kajian
- Baltimore, MD31 kajian
- San Antonio, TX31 kajian
- Philadelphia, PA26 kajian
- Tampa, FL26 kajian
- Durham, NC24 kajian
Kajian lain di Salt Lake City
- Kanser Paru-paru Bukan Sel Kecil31 kajian
- Kanser (semua jenis)27 kajian
- Kanser Payudara27 kajian
- Kanser Kolorektal22 kajian
- Kanser Paru-paru21 kajian
- Melanoma21 kajian
- Mieloma Pelbagai21 kajian
- Kanser Metastatik20 kajian
- Kanser Ovari19 kajian
- Obesiti18 kajian
- Leukemia Mieloid Akut17 kajian
- Kegagalan Jantung17 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.